AKT1 and breast carcinoma: Other alterations that can lead to hyperactivation of the PI3K pathway in breast cancer include ERBB2 and AKT mutations, and deletions, nonsense and loss-of-function missense mutations in the tumor suppressor PTEN (20, 21).